M&A Deal Summary |
|
|---|---|
| Date | 2021-05-04 |
| Target | GamaMabs Pharma - AMHR2 Antibody Technology |
| Sector | Life Science |
| Buyer(s) | Exelixis |
| Sellers(s) | GamaMabs Pharma |
| Deal Type | Divestiture |
| Deal Value | 5M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 1,310 |
| Revenue | 1.8B USD (2023) |
Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Exelixis was founded in 1994 and is based in Alameda, California.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector (Life Science) | 3 of 3 |
| Type (Divestiture) | 1 of 1 |
| Country (France) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-01-14 |
X-Ceptor Therapeutics
San Diego, California, United States X-Ceptor Therapeutics, Inc. discovers and develops novel small molecule therapeutics that modulate nuclear receptors. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2013 |
| Sector | Life Science |
| Revenue | 6M EUR (2021) |
GamaMabs Pharma is an immuno-oncology biotechnology company, provides the development of optimized antibodies targeting AMHR2 for the treatment of cancer. The company develops low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through a breakthrough activation of immune cells. GamaMabs Pharma was founded in 2013 and is based in Toulouse, France.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (France) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
